Stay updated on Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRecruitment status now indicates no participants are being sought, and new guidance sections were added to help users read the study record and join the study. The revision tag was updated to v3.6.0 and the Intervention/Treatment heading formatting was adjusted.SummaryDifference0.6%

- Check17 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5, indicating a minor update to the page version.SummaryDifference0.1%

- Check39 days agoChange Detected- The page now displays Revision: v3.5.4, replacing v3.5.3. This indicates a version update to the page's revision metadata.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page’s interface/release revision updated from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision: v3.5.2 replaces v3.5.0 on the page.SummaryDifference0.1%

- Check96 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.